Why contract manufacturers set high minimums
10,000-unit minimums are often the first financial obstacle for founders who contact us. The standard MOQ at most contract manufacturers means committing roughly 500,000 to 600,000 INR to inventory before a sale is confirmed. For a brand testing a formula in a focused market, that is more than a cost. It is a risk structure that may not fit the business stage.
What the capital commitment means in practice
Fixed-line manufacturers organize around volume efficiency. A 50,000-capsule run requires the same physical setup as 2,000 capsules: ingredient weighing and staging, capsule-filler calibration, in-process weight checks, and cleaning between batches. Spread across 50,000 units, setup contributes little per unit. Spread across 2,000, the economics no longer work for the manufacturer.
This is less a policy choice than a fixed-line cost constraint. Cleaning and changeover between product runs on a dedicated capsule line can take four to six hours. That time must be recovered somewhere, so the MOQ ensures each run produces enough revenue to justify the line time.
For brands already at the volume stage, this structure can work well. During validation, it creates a capital barrier that actual demand may not justify.
How flexible scheduling changes unit economics
Consider a founder developing a botanical adaptogen blend for a specific wellness segment. The formula, target customer, and plan for two or three online channels are ready, but realistic demand is 300 to 600 units in the first 90 days. Producing 10,000 units would leave roughly 9,400 in storage, with labeling and packaging paid for on units that may not ship for 18-24 months. The formula might also need revision after customer feedback.
That feedback can change a live product in ways a formulation brief cannot predict. The capsule may be too large for daily compliance, the serving size may need to change, or a complementary ingredient may improve the positioning. Producing 10,000 units first means carrying unsellable inventory or launching with a formula that is difficult to revise.
The pilot batch as a validation tool
At Leumas, we built our production floor around AI-assisted batch scheduling for this problem. Rather than keeping one product on the line until a minimum quantity is reached, the system groups compatible products and sequences them so they share changeover cost.
Two capsule-fill batches can run back-to-back when their ingredients differ but their fill equipment, operating temperature range, and cleaning protocol class match. The setup overhead is distributed across both. A 500-unit vitamin D and K2 blend and a 500-unit magnesium glycinate complex can share a production window, making both economically viable where neither would work alone on a fixed line.
Small-batch pricing is not the same as volume pricing. The per-unit price at 500 units is higher than at 5,000, which is higher than the price at 25,000. That scaling is expected. Flexible scheduling makes the 500-unit pilot financially workable, rather than merely available in theory.
What pilot batches do not cover
A 500-unit pilot from our facility takes 6-8 weeks from order confirmation and delivers finished product with the same documentation package as a full production run: a Certificate of Analysis, batch record digest, and ingredient traceability report. The product is fully sellable, and the documentation is what a retailer or distributor would ask for.
The pilot is therefore not a prototype. It is a first production run sized to keep financial exposure aligned with market validation. After sell-through and formula confirmation, moving to 5,000 units reduces per-unit cost by 30-40 percent and shortens lead time to 4-6 weeks. The formula specification, raw-material sourcing, and batch-record baseline carry forward.
At 25,000 units, the volume tier becomes the steady production route for brands with confirmed demand. Standard capsule formats cost 33-48 INR per unit, depending on formula complexity.
Reading the MOQ question correctly
We are not saying a 500-unit pilot is free or without commitment. It includes a one-time line validation charge for first-run checks on a new formula at our facility. That charge appears in the batch quote and does not recur for later runs of the same formula. We are saying the first-run cost per unit is higher, even within the same MOQ tier.
Pilots work best with standard dosage forms: hard capsules, powder blends, and standard gummies. Unusual coating requirements, specialized delivery systems such as enteric coating or time-release, and novel excipient combinations not previously processed on our floor require a feasibility assessment. We will not confirm pilot economics until the formula fits the flexible scheduling model.
There is also a practical requirement for a complete formula specification, including declared ingredient quantities and fill-weight targets. We do not finalize formulations within the pilot service. Formulation development is available separately as a prior step for brands without a finished specification.
The MOQ question is really about brand stage. With validated demand and a formula customers already buy, a high MOQ from a high-volume manufacturer may be appropriate. Volume pricing is lower per unit, established runs have faster lead times, and the documentation process is proven.
During formula validation, real customer behavior is still confirming the product and positioning. The MOQ should fit that stage. A 500-unit pilot at a higher per-unit cost is usually the sounder financial structure when the eventual scaling formula is not yet certain.
We designed our batch tiers around the reality that supplement brands often spend 6-18 months in validation before their core line is clear. The pilot tier gives that work room to happen without inventory that could sink the business if the formula changes.